PSYCHOSIS IN PARKINSONS-DISEASE - DIAGNOSIS AND TREATMENT

被引：20

作者：

DORAISWAMY, M ^{[1
]}

MARTIN, W ^{[1
]}

METZ, A ^{[1
]}

DEVEAUGHGEISS, J ^{[1
]}

机构：

[1] GLAXO INC,CNS,CLIN RES GRP,RES TRIANGLE PK,NC 27709

来源：

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 1995年 / 19卷 / 05期

关键词：

ATYPICAL NEUROLEPTICS; DOPAMINE; PARKINSONS DISEASE; PSYCHOSIS; SEROTONIN;

D O I：

10.1016/0278-5846(95)00114-B

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

1. This article reviews the prevalence, diagnosis, pathophysiology and management of psychosis in Parkinson's disease. 2. Psychosis in Parkinson's disease has been associated with all antiparkinsonian medications. The most common symptoms are vivid disturbing dreams, visual hallucinations and paranoid delusions. 3. The emergence of psychosis reduces the patient's functional capacity and increases caregiver burden. It also poses a therapeutic dilemma because effective treatment of psychotic symptoms may result in worsening of motor symptoms and vice versa. 4. Increased physician awareness is essential for proper diagnosis and management. Withdrawal of anticholinergic medications and amantadine followed by levodopa dose adjustment is effective in many patients. 5. Atypical neuroleptics, in low doses, may be successful when other measures have failed. However, these agents are not approved for treating Parkinsonian psychosis and must be considered as investigational therapies.

引用

页码：835 / 846

页数：12

共 28 条

[21]

PALFREYMAN MG, 1992, NOVEL ANTIPSYCHOTIC DRUGS, P211

[22] CLOZAPINE FOR PSYCHOSIS IN PARKINSONS-DISEASE [J].